Hospitalizations

• 最近の研究により、更新されたワクチン製剤が、昨シーズンの健康な成人における救急外来の受診および入院を約50パーセント減少させたことが示されました。 • この大幅な有効性の向上は、ワクチン開発および公衆衛生保護戦略における大きな前進を意味します。 • これらの知見は、2026年4月28日付のCIDRAP最新のワクチン政策状況レポートに記録されている通り、米国におけるワクチン政策の進展に寄与しています。

• The U.S. daily COVID-19 case average increased by 13.3% over the past week, though hospitalizations continue to decline according to federal data. • About 48,000 patients are currently hospitalized with COVID-19, representing a decrease of nearly 104,000 patients over the past eight weeks, with hospital admissions down 11.7% weekly. • Alaska has the highest infection rate in the nation, followed by Montana, North Dakota, and Wyoming, while Puerto Rico, Florida, and Hawaii report the lowest rates.

• The SPIRIT-HF study, presented at ACC.26 in New Orleans (March 28-30, 2026), found that spironolactone increased hospitalizations and serious adverse events in patients with HFpEF (heart failure with preserved ejection fraction) or HFmrEF (mildly reduced ejection fraction). • Results raise significant safety questions about the drug's efficacy in these patient populations, potentially challenging current treatment protocols. • The findings were presented to cardiologists and cardiovascular specialists at the American College of Cardiology's annual conference, the largest gathering of heart disease specialists.

• Respiratory syncytial virus (RSV) hospitalizations declined 42% in the week ending March 20, 2026, compared to the peak surge in February, according to CDC surveillance data. • The decline follows the introduction of the first RSV vaccines approved for adults over 60 and high-risk populations, with over 8 million doses administered since January. • RSV typically causes severe disease in infants and older adults; the new vaccines represent a major breakthrough after decades of failed vaccine development efforts.